Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that ...
Q4 2025 earnings call recap: 2026 revenue/EBITDA guidance, AI-driven cost cuts, ARR/retention trends, and new markets—read now.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results